Iovance falls 12% despite Q3 beats; reaffirms 2024 revenue guidance

filo Iovance Biotherapeutics ( NASDAQ: IOVA ) is down 12% in after-hours trading Thursday despite posting Q3 results that beat on both lines and reaffirming its fiscal 2024 revenue guidance. The biotech still sees full-year product sales of $160M-$165M. Revenue consensus is $162.

71M. The company also reiterated its.